Although there may be distinct differences in irAE rates between cancer types, these may be confounded by the treatment regimen given—i.e., anti-CTLA-4 is more likely to be used in melanoma or RCC vs NSCLC; therefore, the differences in irAE rates may be at least partially attributed to differences in regimen used between cancer types. Here, CTLA4 is linked to cancer.